Reading a clinical trial paper on migraine management can sometimes feel like navigating a maze of statistical jargon
In the landmark 2014 study on telcagepant published in Neurology, researchers used precise, standardized definitions based on the International Headache Society (IHS) criteria
Here is how key trial endpoints were defined:
Headache Day: Any calendar day during which a patient experiences headache pain lasting more than 30 minutes, or any headache duration requiring acute medication
. If pain persists past midnight into a second day, it is counted as a distinct, new headache day . Migraine/Probable Migraine Day: A headache day accompanied by at least one classic associated symptom, such as visual aura, photophobia (light sensitivity), phonophobia (sound sensitivity), nausea, or vomiting
. Migraine Attack: Any continuous migraine occurrence spanning up to two consecutive calendar days
. Pain persisting beyond two full days is categorized as a new attack . 50% Responder Rate: The proportion of trial participants who achieve at least a 50% reduction in their average monthly headache or migraine days compared to their baseline
.
In the telcagepant trial, primary efficacy was judged by the change in mean monthly headache days over 12 weeks
Why do these tight definitions matter? In clinical trials, consistency is everything